Skip Navigation

European Heart Journal 1994 15(4):528-533;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ALBO, C.
Right arrow Articles by DUBOIS-RANDE, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ALBO, C.
Right arrow Articles by DUBOIS-RANDE, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure

C. ALBO, J. P. SAAL, D. LELLOUCHE, R. HABBAL, C. BENVENUTI, P. DELEUZE*, D. LOISANCE*, A. CASTAIGNE and J. L. DUBOIS-RANDE

Departement de Cardiologie, INSERM U2 Hopital Henri Mondor Creteil 94010, France
*CNRS UA 1431, Hopital Henri Mondor Creteil 94010, France

Received 6 July 1993; revised 7 October 1993; .

Correspondence Dr Jean Luc Dubou-Randè, Service de cardiologie, Hopital Henri Mondor, Creteil 94010, France

Abstract

This study was undertaken to assess the haemodynamic effects of the combined infusion of prostacyclin and piroximone, a phosphodiesterase inhibitor, in 18 patients with severe congestive heart failure. Right heart catheterization was performed with a Swan-Ganz thermodilution catheter and arterial blood pressure was monitored using a radial line. After baseline haemodynamic measurements, prostacyclin was administered in all patients at the incremental infusion rate of 2, 4, 6 and 8 and 10 ng. kg–1. min–1 during 15min each. After recovery of baseline haemodynamics, patients were randomly assigned to the piroximone infusion rate of 5 or 10µg. kg–1. min–1 or placebo. After 24 h piroximone or placebo infusion, the same prostacyclin protocol was applied. Prostacyclin infusion added to piroximone resulted in a significant improvement in haemodynamics, as compared to the group receiving prostacyclin added to placebo. As compared to the curve observed with the placebo infusion, 10 ng. kg–1. min–1 prostacyclin infusion resulted in a further increase in cardiac index, by 41 and 38% (P<0·01) at the piroximone-infusion rates of 5 and 10 ng. kg–1. min–1, respectively, whereas systemic vascular resistance decreased by 25 and 21%, respectively (P<0·01). Additionally, a further decrease in pulmonary capillary wedge pressure by 13 and 11% (P<0·05) and in pulmonary vascular resistance by 21 and 19% (P<0·05) was observed at the piroximone-infusion rates of 5 and 10µig. Kg–1. min–1, respectively. Consequently, stroke work index increased significantly, as compared to the group receiving prostacyclin added to placebo. This haemodynamic improvement occurred without significant changes in heart rate and mean arterial pressure. Thus, this study shows that in patients with severe congestive heart failure, short-term infusion of prostacyclin is safe and has additive haemodynamic effects on phosphodiesterase inhibitors.

Key Words: Congestive heart failure • piroximone • prostacyclin • haemodynamics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.